RT Journal Article
SR Electronic
T1 What is known about the determinants of developing antipsychotic-induced metabolic syndrome and interventions to address them for community dwelling adults: a scoping review protocol
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.01.05.22283663
DO 10.1101/2023.01.05.22283663
A1 Good, Emma
A1 Bhattacharya, Debi
A1 Maden, Michelle
A1 Scott, Sion
YR 2024
UL http://medrxiv.org/content/early/2024/01/31/2023.01.05.22283663.abstract
AB Introduction Antipsychotics are the primary treatment for severe mental health conditions. Whilst antipsychotics are effective at improving psychiatric outcomes, approximately 80% of people will experience metabolic side effects (MSEs), characterised by weight gain, lipid disturbance and glucose dysregulation. Antipsychotic-induced MSEs are associated with a two-fold increased risk of developing coronary heart disease and a five-fold risk of developing type 2 diabetes.Gender, ethnicity, age, and family history are reported non-modifiable determinants of developing antipsychotic-induced MSEs and indicate who is at highest risk. However, it is not clear which determinants are most significant to inform targeting interventions for high-risk individuals.Antipsychotics induce increases in calorie intake and sedentary behaviours. Behavioural determinants are modifiable and provide potential intervention targets, however, the extent to which they have been studied and targeted is unclear.The literature describes the testing of non-pharmacological interventions to target behaviours. However, few studies report clinically significant attenuation of MSEs, and the preferred healthcare setting to deliver an intervention to prevent antipsychotic-induced MSEs is yet to be established.Methods and analysis This review will adhere to the Joanna Briggs Institute guidance for scoping reviews and the PRISMA-ScR checklist (Appendix 1). Relevant electronic databases will be searched. Qualitative, quantitative and mixed method study designs, and evidence syntheses will be considered. One reviewer will independently screen titles and abstracts, with a 20% sample checked by two reviewers. Full text screening will be undertaken by one reviewer with a 10% sample checked by another. Data will be extracted and synthesised to address the research objectives.Ethics and dissemination Ethics approval is not required. Findings will be disseminated through professional networks, conference presentations and publication in a scientific journal.medRxiv registration details DOI:10.1101/2023.01.05.22283663STRENGTHS AND LIMITATIONS OF THIS STUDYThis study will be the first to systematically identify the knowledge gaps the in body of literature relating to the modifiable and non-modifiable determinants of antipsychotic-induced metabolic side effects (MSEs) in community dwelling adults, the non-pharmacological interventions to target behaviours that have previously been implemented to prevent and/or treat antipsychotic-induced MSEs and their success or non-success, and the preferred context of delivery of such interventions from the point of view of the individuals affected by antipsychotic-induced MSEs. Insights from these can highlight areas to inform further research in this area.This study will link modifiable determinants of antipsychotic-induced MSEs to the theoretical domains framework (TDF), which can be linked to a taxonomy of behaviour change techniques to inform components for a future intervention.The review will take a rigorous approach, adhering to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses-Scoping Review (PRISMA-ScR) guidelines.Only literature published in English will be included. This could potentially limit the diversity of literature captured in the review.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study did not receive any fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical approval is not required for this scoping review as it will only involve secondary analysis of publicly available, anonymised data.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.